Why the study?
Does flecainide suppress premature ventricular contractions in a patient refractory to catheter ablation and other antiarrhythmic drugs?
Does flecainide suppress premature ventricular contractions in a patient refractory to catheter ablation and other antiarrhythmic drugs?
Flecainide may be an effective treatment option for frequent premature ventricular contractions originating from the papillary muscle that are refractory to catheter ablation and other antiarrhythmic drugs.
Answers are grounded in this paper and cite their sources.
Flecainide may suppress refractory papillary PVCs; leaves open its role in reversible cardiomyopathy pending controlled studies.
We describe suppression of frequent premature ventricular contractions from the papillary muscle by flecainide in a patient with a history of reversible cardiomyopathy associated with arrhythmia and ineffective antiarrhythmic therapy with other IC and III class drugs, as well as refractory to repeated catheter ablation.
No takes yet. Share an insight, caveat, or question.
Shchukina et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: